secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106529
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026
--------------------------------------------------------------------------------

- Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.
- Phase 3 X-TOLE2 (focal seizures) patient recruitment complete; topline data expected early 2026.
- Phase 1 studies underway for XEN1120 (Kv7) and XEN1701 (Nav1.7) pain candidates.
- Darren Cline appointed Chief Commercial Officer to lead commercial build for azetukalner launch.
- Cash $624.8M as of June 30, 2025; funding expected into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/0000950170-25-106529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/xene-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer